Elucidating the mechanisms and consequences of clinical HIV-1 resistance to the CCR5 antagonist maraviroc

阐明 HIV-1 对 CCR5 拮抗剂马拉韦罗的临床耐药机制和后果

• 批准号: nhmrc : 1059394
• 负责人: A/Pr Paul Ramsland
• 金额: $ 41.52万
• 依托单位: RMIT University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/elucidating-mechanisms-consequences-antagonist-maraviroc/454754
• 关键词: Elucidating; mechanisms; consequences; clinical; HIV

CCR5 antagonists are a new class of anti-HIV drug, and maraviroc (MVC) is the only CCR5 antagonists that is licensed for use as a HIV treatment. Like all HIV treatments, drug resistance to MVC can develop in patients. This study will determine the mechanism of how HIV becomes resistant to MVC, which will permit the development of improved, second generation CCR5 antagonists, and will reveal ways to determine which patients are more likely to develop MVC resistance.

CCR5拮抗剂是一种新型抗HIV药物，马拉韦罗（MVC）是唯一被许可用作HIV治疗的CCR5拮抗剂。像所有的艾滋病治疗一样，对MVC的耐药性可以在患者中发展。这项研究将确定HIV如何对MVC产生耐药性的机制，这将允许开发改进的第二代CCR5拮抗剂，并将揭示确定哪些患者更有可能产生MVC耐药性的方法。